Snap-8 10mg

Description

Strength: 10mg
CAS: 868844-74-0
Chemical Formula: C₄₁H₇₀N₁₆O₁₆S
Molecular weight: 1075.16 g/mol
Peptide Sequence: Acetyl-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2
Synonyms: Acetyl Octapeptide-3
Storage: Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
Shelf life: 24 months from the manufacturing date.

SNAP-8 is a synthetic octapeptide, also known as acetyl octapeptide-3, with the amino acid sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp (EEMQRRAD). The SNAP-8 peptide has a defined molecular weight of approximately 1,075 Da, CAS Number: 868844-74-0, and is produced through controlled solid-phase peptide synthesis to support structural accuracy and batch consistency.

This product is supplied as a high-purity, lyophilized powder in a sealed laboratory vial. SNAP-8 is provided strictly as a laboratory research reagent for experimental systems examining synaptic protein interactions and neuromuscular signaling mechanisms.

• Synthetic octapeptide with verified purity and identity
• Lyophilized powder supplied in a sealed research vial
• Defined amino acid sequence (EEMQRRAD) with documented molecular specifications
• Designed as a SNAP-25–mimetic research peptide
• Suitable for in vitro and controlled preclinical studies
• Stable when stored under recommended frozen conditions

SNAP-8 is an octapeptide designed to mimic the N-terminal domain of the SNAP-25 protein. It functions as a competitive inhibitor of SNAP-25, a core component of the SNARE complex (Soluble N-ethylmaleimide-sensitive factor Attachment protein Receptor). Through competitive binding to syntaxin and synaptobrevin, SNAP-8 destabilizes SNARE complex formation, which inhibits calcium-dependent acetylcholine exocytosis at the neuromuscular junction.

Under normal neuromuscular transmission, the SNARE complex forms when SNAP-25 associates with syntaxin and synaptobrevin, enabling synaptic vesicle fusion with the presynaptic membrane and acetylcholine release. SNAP-8 competes with SNAP-25 for these binding sites, preventing proper SNARE assembly. This disruption interferes with the molecular machinery required for vesicle fusion and neurotransmitter exocytosis.

By reducing acetylcholine release at the neuromuscular junction, SNAP-8 decreases activation of nicotinic receptors on skeletal muscle fibers, resulting in reduced muscle contraction. This mechanism parallels that of other SNARE-targeting agents, although SNAP-8 acts through competitive inhibition rather than proteolytic cleavage.

Research applications focus on peptide–protein binding interactions involving SNAP-25, syntaxin, and synaptobrevin, with studies evaluating competitive binding kinetics, SNARE destabilization efficiency, and structure-function relationships between SNAP-8 and native SNAP-25. Experimental models include isolated neuromuscular preparations, cultured myotubes innervated by neurons, synaptosomal systems, and whole-animal models that assess motor function and muscle contraction under controlled laboratory conditions.

These study designs often use standardized materials, and many groups buy SNAP-8 peptide to maintain consistency across assays.

Published laboratory studies report SNAP-8 dosing strategies that vary by experimental model and research objective. Concentrations typically range from nanomolar to micromolar levels in in vitro systems, depending on the SNARE proteins evaluated and the desired degree of SNARE complex inhibition.

Observed endpoints include changes in SNARE complex assembly, measured by co-immunoprecipitation or surface plasmon resonance; quantification of acetylcholine release; electrophysiological recordings of synaptic transmission; measurements of muscle contraction force; and visualization of synaptic vesicle docking and fusion events. These findings inform experimental design in settings where laboratories order SNAP-8 peptide for controlled mechanistic analysis and do not represent applied or clinical outcomes.

SNAP-8 should be stored in its lyophilized form at –20°C or lower, protected from light and moisture. After reconstitution, solutions should be prepared using sterile laboratory techniques and handled according to established research protocols, with care taken to avoid repeated freeze–thaw cycles.

This material should be handled only by trained personnel in controlled laboratory environments. Laboratories that buy SNAP-8 peptide are responsible for compliance with all applicable research, safety, and handling regulations.

References

https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2020.572923/full

https://pmc.ncbi.nlm.nih.gov/articles/PMC11762834/

https://www.ncbi.nlm.nih.gov/books/NBK470413/

https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2020.610964/full

https://pubmed.ncbi.nlm.nih.gov/7961655/

Compliance Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use.